Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition

SIMPLE SUMMARY: For the small subset of pancreatic ductal adenocarcinoma (PDAC) patients with loss-of-function mutations to BRCA1/2 or PALB2, both first-line and maintenance therapy differs significantly. These mutations confer a loss of double-strand break DNA homologous recombination (HR), substan...

Descripción completa

Detalles Bibliográficos
Autor principal: Principe, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869830/
https://www.ncbi.nlm.nih.gov/pubmed/35205643
http://dx.doi.org/10.3390/cancers14040897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869830/
https://www.ncbi.nlm.nih.gov/pubmed/35205643
http://dx.doi.org/10.3390/cancers14040897

Ejemplares similares